Cornelius Miething
Overview
Explore the profile of Cornelius Miething including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
4117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duque-Afonso J, Veratti P, Rehman U, Herzog H, Mitschke J, Greve G, et al.
Int J Cancer
. 2024 Aug;
155(11):2068-2079.
PMID: 39146497
Aberrant gene expression patterns in acute myeloid leukemia (AML) with balanced chromosomal translocations are often associated with dysregulation of epigenetic modifiers. The AML1/ETO (RUNX1/MTG8) fusion protein, caused by the translocation...
2.
Kuehn J, Metzger P, Neidert N, Matysiak U, Grassel L, Philipp U, et al.
NPJ Precis Oncol
. 2024 Aug;
8(1):180.
PMID: 39143272
Despite major advances in molecular profiling and classification of primary brain tumors, personalized treatment remains limited for most patients. Here, we explored the feasibility of individual molecular profiling and the...
3.
Michaelis J, Himmelsbach R, Metzger P, Lassmann S, Borries M, Werner M, et al.
Urol Int
. 2024 Apr;
108(5):383-391.
PMID: 38626735
Introduction: Personalized medicine poses great opportunities and challenges. While the therapeutic landscape markedly expands, descriptions about status, clinical implementation and real-world benefits of precision oncology and molecular tumor boards (MTB)...
4.
Maas-Bauer K, Stell A, Yan K, de Vega E, Vinnakota J, Unger S, et al.
Nat Commun
. 2024 Jan;
15(1):446.
PMID: 38199985
Patients with corticosteroid-refractory acute graft-versus-host disease (aGVHD) have a low one-year survival rate. Identification and validation of novel targetable kinases in patients who experience corticosteroid-refractory-aGVHD may help improve outcomes. Kinase-specific...
5.
Dieterle M, Mostufi-Zadeh-Haghighi G, Kus J, Wippel C, Brugger Z, Miething C, et al.
Ann Hematol
. 2023 Sep;
102(12):3639-3641.
PMID: 37710140
No abstract available.
6.
Jaeger A, Gambheer S, Sun X, Chernyakov D, Skorobohatko O, Mack T, et al.
Blood
. 2023 Jan;
141(23):2824-2840.
PMID: 36696631
Peripheral T-cell lymphomas (PTCLs), especially angioimmunoblastic and follicular TCLs, have a dismal prognosis because of the lack of efficient therapies, and patients' symptoms are often dominated by an inflammatory phenotype,...
7.
Frank B, Ihorst G, Herget G, Schafer H, Neubauer J, Calba M, et al.
Ann Hematol
. 2022 Dec;
102(3):603-611.
PMID: 36464695
The established standard to ensure state-of-the-art cancer treatment is through multidisciplinary tumor boards (TBs), although resource- and time-intensive. In this validation study, the multiple myeloma (MM)-TB was reexamined, aiming to...
8.
Holzen L, Syre K, Mitschke J, Brummer T, Miething C, Reinheckel T
Front Oncol
. 2022 Oct;
12:960109.
PMID: 36313646
Proteases are known to promote or impair breast cancer progression and metastasis. However, while a small number of the 588 human and 672 murine protease genes have been extensively studied,...
9.
Ho J, Schmidt D, Lowinus T, Ryoo J, Dopfer E, Gonzalo Nunez N, et al.
Blood
. 2022 Jul;
140(10):1167-1181.
PMID: 35853161
Patients with acute myeloid leukemia (AML) often achieve remission after allogeneic hematopoietic cell transplantation (allo-HCT) but subsequently die of relapse driven by leukemia cells resistant to elimination by allogeneic T...
10.
Holzen L, Mitschke J, Schonichen C, Hess M, Ehrenfeld S, Boerries M, et al.
Theranostics
. 2022 Jun;
12(9):4348-4373.
PMID: 35673573
Rationale: PI3K/mTOR signaling is frequently upregulated in breast cancer making inhibitors of this pathway highly promising anticancer drugs. However, PI3K-inhibitors have a low therapeutic index. Therefore, finding novel combinatory treatment...